Physician profile
Ali Malik
NPI 1144566944
$12,833.06
in general payments reported to CMS, 2019-2025
26 companies · $4,930 in 2025
The $4,930 reported for 2025 was more than what 97% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,211 · 2020: $121 · 2021: $2,504 · 2022: $1,202 · 2023: $918 · 2024: $949 · 2025: $4,930.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,796 · Travel and Lodging: $970 · Education: $30.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,795.98 |
| Travel and Lodging | $970.41 |
| Education | $30.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,452.01 | 2023-2025 | Proclaim, Eterna, Durata |
| Spinal Simplicity, LLC | $2,224.76 | 2021-2025 | Ha Minuteman G3-R |
| Medtronic USA, INC. | $1,663.71 | 2019 | |
| Boston Scientific Corporation | $1,610.10 | 2019-2025 | Intracept, General - Pain Management, Wavewriter Alpha Prime 16 |
| Stimwave Technologies Incorporated | $1,075.31 | 2020-2022 | |
| Nevro Corp. | $1,000.68 | 2019-2024 | Senza |
| Globus Medical, INC. | $732.36 | 2025 | Senza |
| Biotronik Nro, INC. | $497.70 | 2025 | Prospera |
| Curonix LLC | $304.49 | 2023-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Saluda Medical Americas, INC. | $187.63 | 2025 | Evoke |
| Abbvie INC. | $149.72 | 2022-2024 | |
| Astrazeneca Pharmaceuticals Lp | $121.84 | 2025 | Wainua |
| Medtronic, INC. | $109.58 | 2022-2024 | Intellis Adaptivestim |
| Spr Therapeutics, INC | $106.36 | 2025 | Sprint Pns System |
| Scilex Pharmaceuticals INC. | $104.74 | 2021-2023 | Ztlido |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $85.81 | 2025 | |
| Collegium Pharmaceutical, INC. | $80.69 | 2022-2025 | Xtampza |
| Si-Bone, INC. | $64.92 | 2024-2025 | |
| Grt US Holding, INC. | $64.09 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.51 | 2023 | Relistor |
| Redhill Biopharma INC. | $43.28 | 2020-2021 | |
| Biodelivery Sciences International, INC. | $35.21 | 2020-2021 | |
| Orthofix Medical, INC. | $20.27 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $20.12 | 2023 | Seglentis |
| Depuy Synthes Sales INC. | $13.99 | 2019 | |
| Trice Medical, INC. | $10.18 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.